興齊眼藥(300573.SZ):擬與自貿區瀋陽片區管委會簽署項目投資協議 總投資6.37億元
格隆匯6月28日丨興齊眼藥(300573.SZ)公佈,為滿足公司戰略發展需要,並基於互利互惠、合作共贏的原則,公司擬與自貿區瀋陽片區管委會簽署《項目投資協議》。
該次項目總投資額為6.37億元,公司擬在政策期限(5年)內分批次投入,投資內容包括但不限於興齊眼科藥物研發中心建設、藥物研發等。公司將通過出讓方式取得相關用地,以保障前述投資項目的用地需求。
此外,為優化公司整體業務規劃,公司取得前述用地後,計劃將部分土地用於公司2020年度向特定對象發行股票的募投項目之一的“研發中心建設及新藥研發項目”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.